...
首页> 外文期刊>European Journal of Surgical Oncology: The Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology >Prognosis and postoperative lymphocyte count in patients with hepatocellular carcinoma who received intraoperative allogenic blood transfusion: a retrospective study.
【24h】

Prognosis and postoperative lymphocyte count in patients with hepatocellular carcinoma who received intraoperative allogenic blood transfusion: a retrospective study.

机译:接受术中同种异体输血的肝细胞癌患者的预后和术后淋巴细胞计数:一项回顾性研究。

获取原文
获取原文并翻译 | 示例

摘要

AIMS: The effect of perioperative blood transfusion on the survival of hepatocellular carcinoma (HCC) has not been fully investigated. To clarify the prognostic value of intraoperative allogenic blood transfusion, we conducted a comparative retrospective analysis of 224 patients with HCC who underwent hepatic resection. METHODS: We compared clinicopathologic background and survival after hepatic resection between patients who received intraoperative blood transfusion (n=101) and those who did not (n=123). RESULTS: Patients with blood transfusion had a larger tumor and more frequent vascular invasion than those without blood transfusion. The 5-year cancer-related survival rate after hepatic resection, but not the disease-free survival rate, was significantly lower in patients who underwent blood transfusion than in those who did not (38.3% vs. 66.7%, P<0.01). Multivariate analysis showed intraoperative blood transfusion (P=0.02), microscopic portal invasion (P<0.01), and preoperative serum alpha-fetoprotein elevation (P=0.03) to be independent risk factors for poor outcome after hepatic resection. The negative effect of blood transfusion on postoperative survival was observed only in patients with a tumor larger than 50mm in diameter. The absolute peripheral blood lymphocyte count on postoperative day 1 was significantly lower in patients who underwent blood transfusion (880/mm(3)) than in those who did not (1081/mm(3)) (P<0.01). CONCLUSIONS: Our data suggest that intraoperative blood transfusion results in immunosuppression in the early postoperative period, allowing for progression of residual HCC after resection. Therefore, intraoperative allogenic blood transfusion should be avoided in patients with resectable HCC, particularly in those with a large tumor.
机译:目的:围手术期输血对肝细胞癌(HCC)生存的影响尚未得到充分研究。为了阐明术中异体输血的预后价值,我们对224例行肝切除术的HCC患者进行了比较回顾性分析。方法:我们比较了接受术中输血的患者(n = 101)和未接受术中输血的患者(n = 123)的肝切除术后的临床病理背景和存活率。结果:与不输血的患者相比,输血患者的肿瘤更大,血管侵犯更为频繁。输血患者的肝切除后5年癌症相关生存率,而非无病生存率,显着低于未输血患者(38.3%vs. 66.7%,P <0.01)。多变量分析显示术中输血(P = 0.02),镜下门静脉侵犯(P <0.01)和术前血清甲胎蛋白升高(P = 0.03)是肝切除术后不良预后的独立危险因素。仅在直径大于50mm的肿瘤患者中观察到输血对术后生存的负面影响。接受输血的患者(880 / mm(3))术后第1天的绝对外周血淋巴细胞计数显着低于未接受输血的患者(1081 / mm(3))(P <0.01)。结论:我们的数据表明,术中输血会在术后早期导致免疫抑制,从而使切除后残留的肝癌进展。因此,对于可切除的HCC患者,尤其是肿瘤较大的患者,应避免术中异体输血。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号